ResMed Inc.

▲ Bull Case

• ◆GLP-1 confirmed net positive: new CPAP starts accelerate +15–20%. If independent clinical studies confirm RMD's internal data (GLP-1 users +10% more CPAP initiations) AND Zepbound's FDA approval drives mass OSA diagnosis, the GLP-1 narrative flips 180°. RMD goes from 'GLP-1 victim' to 'GLP-1 beneficiary' — massive sentiment re-rating from 28x to 38–40x P/E. At $13 EPS × 38x = $494 (+93%).
• ◆Philips consent decree extended or denied; market share holds above 58%. If the FDA determines Philips' manufacturing quality cannot meet CPAP device standards within 2027–2028, a permanent or extended consent decree would leave RMD with 58–62% market share indefinitely. Combined with market growth of 5–8%/yr, this is the maximum upside scenario for the installed base thesis.
• ◆SaaS (Brightree/MatrixCare) becomes 20% of revenue and re-rates the entire multiple. If SaaS grows 15%/yr (to ~$800M by FY2027) and reaches 20% of blended revenue with 80%+ gross margins, institutional investors may apply a 'software company' composite valuation. Sum-of-parts: Device business at 25x EPS + SaaS at 35x EPS = blended 28–30x — structural upside beyond simple P/E comps.

▼ Bear Case

• ◆GLP-1 drugs reduce CPAP new starts by 6–8%/yr. Real-world observational studies show patients prescribed GLP-1 achieving >12–15% weight loss have a 40–50% resolution of their OSA diagnosis. If only 8–10% of new CPAP candidates take GLP-1 but those patients have 50% OSA resolution, net new CPAP starts decline 4–5%. Over 5 years, device market growth slows from 7% to 3% — multiple compression to 22x warranted.
• ◆Philips re-enters U.S. aggressively with 20% price discount; market share falls to 50% in 3 years. Philips has massive manufacturing scale and brand recognition in sleep therapy. If it returns with a competitive AirSense alternative at $150–200 below RMD pricing, DMEs have financial incentive to switch. 50% market share = $250–300M annual revenue loss vs. current trajectory.
• ◆CEO/Chairman duality causes governance failure. Mick Farrell's dual CEO+Chairman role (since FY2023) concentrates authority in ways that have historically led to strategic errors or excessive compensation. Peter Farrell (founder, age 83, consistent Rule 144 seller) creates insider selling overhang. If institutional activism targets the governance structure or a CEO transition occurs without clear succession, valuation discount widens.

“Will GLP-1 drugs (particularly Zepbound/tirzepatide, FDA-approved for OSA in Dec 2024) reduce CPAP market demand, or will increased diagnostic awareness from GLP-1 adoption actually expand the CPAP patient population? The bear says obesity causes OSA in ~50–55% of patients and GLP-1 drugs achieving 15%+ weight loss reduce OSA severity scores by 30–40%, decelerating the device market's growth rate from 7–8%/yr to 3–4% and warranting structural multiple compression. The bull says RMD's 28M-patient real-world data shows GLP-1 users initiate CPAP 10% more often; anatomical OSA is unaffected by weight loss; and GLP-1 discontinuation rates are high (50%+ stop within 12 months), returning patients to CPAP need. The net effect is likely neutral to mildly positive. Key monitor: First independent, large-scale clinical study correlating GLP-1 use with CPAP adherence/discontinuation (expected published 2026–2027).”

• ◆Independent academic study (N>10,000) on GLP-1/CPAP interaction published 2026–2027 — most important binary catalyst
• ◆Q4 FY2026 earnings (Aug 2026): Full FY2026 results, FY2027 guidance, gross margin confirmation at 61–63%
• ◆Philips FDA consent decree status update — timeline extension or resolution determines near-term market share risk
• ◆SaaS ARR formal disclosure for Brightree/MatrixCare — multiple re-rating trigger
• ◆Continued share buyback execution from $1.8B+ annual FCF — per-share value compounding
• ◆CEO/Chairman governance resolution or Lead Independent Director empowerment

• ◆GLP-1 confirmed negative for CPAP demand (VERY HIGH severity, 25% probability) — independent studies showing 20%+ higher CPAP discontinuation in GLP-1 users triggers TKS-1 sell
• ◆GLP-1 severe disruption with 25%+ decline in new CPAP starts (CATASTROPHIC severity, 5% probability)
• ◆Philips re-entry faster/more aggressive than expected with 20% price discount driving market share below 50% (HIGH severity, 25% probability)
• ◆CEO/Chairman governance failure or unplanned CEO transition without named successor (MEDIUM severity, 15% probability)
• ◆SaaS growth disappoints below 7%/yr — undermining the multiple re-rating thesis (MEDIUM severity, 15% probability)
• ◆Gross margin expansion stalls below 61% — structural mix shift thesis impaired (MEDIUM severity, 10% probability)